Project item | Indications | Research phase | Cooperation demands |
BDA202201 | Cancer pain, chemotherapy-induced neuropathic pain, Kashin-Beck disease, diabetic neuralgia, interstitial cystitis, chronic low back pain. | Phase Ⅰ/Ⅱa | License-out or co-development |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TRA-H5253 | Human | Human TrkA / NTRK1 (192-402) Protein, Mouse IgG2a Fc Tag | ![]() |
![]() ![]() |
|
TRA-H5259 | Human | Human TrkA / NTRK1 (33-417) Protein, Mouse IgG2a Fc Tag | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Adenoid Cystic; Thyroid Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Solid tumours; Glucagonoma; Multiple Myeloma; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neoplasms; Glioblastoma; Colonic Neoplasms; Hemangiosarcoma; Carcinoma, Islet Cell; Insulinoma; Carcinoid Tumor; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms | Details |
Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences | Rozlytrek, 罗圣全 | Mainland China | Solid tumours | Roche (China) Holding Ltd | 2019-06-18 | Cholangiocarcinoma; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Melanoma; Brain metastases; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Hepatic Insufficiency; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Ovarian Neoplasms; Breast Neoplasms; Uveal melanoma; Central Nervous System Neoplasms; Neuroendocrine Tumors; Salivary Gland Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Solid tumours; Head and Neck Neoplasms | Details |
Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | Mainland China | Solid tumours | Bayer Healthcare Company Ltd | 2018-11-26 | Solid tumours; Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AK-1830 | AK-1830 | Phase 1 Clinical | Array Biopharma | Inflammation | Details |
HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
SNA-125 | CT-340; SNA-125 | Phase 2 Clinical | Sienna Biopharmaceuticals, Creabilis | Pruritus; Psoriasis; Dermatitis, Atopic | Details |
VMD-928 | VMD-928 | Vm Oncology | Details | ||
XZP-5955 | XZP-5955 | Phase 2 Clinical | Solid tumours | Details | |
FCN-098 | FCN-098; FCN098 | Phase 1 Clinical | Chongqing Fuchuang Pharmaceuticals Research Co Ltd, Fochon Pharmaceuticals Ltd | Solid tumours; Neoplasms | Details |
Altiratinib | DP-5164; DCC-2701; DCC-22701; T-678746713 | Deciphera | Details | ||
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Kyowa Hakko Kirin | Details | ||
ACD-856 | ACD-856 | Alzecure Pharma Ab | Details | ||
VM-902A | VM-902; VM-902A | Vm Discovery | Details | ||
AZD-6918 | AZD-6918 | Astrazeneca Pharmaceutical Co Ltd | Details | ||
Pegcantratinib | CT 327; SNA-120; CT 301/P; K-252a-PEG2K; Pegylated K252A | Cephalon | Details | ||
TQB-3558 | TQB-3558 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours | Details |
PLX-7486 | PLX-7486; PLX7486-TsOH | Daiichi Sankyo Co Ltd | Details | ||
PBI-200 | Phase 2 Clinical | Pyramid Biosciences | Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms | Details | |
VC-004 | VC-004; VC 004; VC004 | Phase 2 Clinical | Jiangsu Weikeer Pharmaceutical Technology Co Ltd | Solid tumours | Details |
HH-30134 | HH-30134 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.